Role of Platelet Inhibition in Microvascular Surgery

Abstract

Thrombosis remains a significant complication of microvascular free tissue transfer. Recent discoveries in the field of vascular biology have led to a greater understanding of thrombogenesis and the pivotal role that platelets play in the formation of a clot. However, current antithrombotic strategies in the clinical practice of free tissue transfer have not typically focused on platelet inhibition. Decades of cardiovascular clinical trials have delineated the essential role of platelet inhibitor therapy in patients with acute coronary syndromes and those undergoing percutaneous coronary interventions. Understanding the current treatment guidelines for antiplatelet therapy across the spectrum of patients with coronary heart disease may provide insights into their use in the prevention and treatment of thrombosis in microvascular surgery. In this review, we examine the current antiplatelet agents in clinical use and discuss the potential role of platelet inhibition in free flap surgery, particularly in the setting of repeated microvascular thrombosis.

Keywords

platelet inhibition - flap surgery - thrombosis - microvascular

• References

• 1 Taylor GI, Daniel RK. The free flap: composite tissue transfer by vascular anastomosis. Aust N Z J Surg 1973; 43 (1) 1-3
• 2 Khouri RK, Cooley BC, Kunselman AR , et al. A prospective study of microvascular free-flap surgery and outcome. Plast Reconstr Surg 1998; 102 (3) 711-721
• 3 Hidalgo DA, Disa JJ, Cordeiro PG, Hu QY. A review of 716 consecutive free flaps for oncologic surgical defects: refinement in donor-site selection and technique. Plast Reconstr Surg 1998; 102 (3) 722-732 , discussion 733–734
• 4 Blondeel PN. One hundred free DIEP flap breast reconstructions: a personal experience. Br J Plast Surg 1999; 52 (2) 104-111
• 5 Greco III JA, Castaldo ET, Nanney LB , et al. Autologous breast reconstruction: the Vanderbilt experience (1998 to 2005) of independent predictors of displeasing outcomes. J Am Coll Surg 2008; 207 (1) 49-56
• 6 Mehrara BJ, Santoro TD, Arcilla E, Watson JP, Shaw WW, Da Lio AL. Complications after microvascular breast reconstruction: experience with 1195 flaps. Plast Reconstr Surg 2006; 118 (5) 1100-1109 , discussion 1110–1111
• 7 Sullivan SR, Fletcher DRD, Isom CD, Isik FF. True incidence of all complications following immediate and delayed breast reconstruction. Plast Reconstr Surg 2008; 122 (1) 19-28
• 8 Selber JC, Kurichi JE, Vega SJ, Sonnad SS, Serletti JM. Risk factors and complications in free TRAM flap breast reconstruction. Ann Plast Surg 2006; 56 (5) 492-497
• 9 Go AS, Mozaffarian D, Roger VL , et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation 2013; 127 (1) 143-152
• 10 Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330 (14) 956-961
• 11 EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336 (24) 1689-1696
• 12 EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352 (9122) 87-92
• 13 ESPRIT Investigators ; Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000; 356 (9247) 2037-2044
• 14 Hamm CW, Heeschen C, Goldmann B , et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999; 340 (21) 1623-1629
• 15 Cohen MG, Pacchiana CM, Corbalán R , et al. Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: results from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Am Heart J 2001; 141 (3) 391-401
• 16 Kong DF, Califf RM, Miller DP , et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98 (25) 2829-2835
• 17 Madan M, Berkowitz SD, Tcheng JE. Glycoprotein IIb/IIIa integrin blockade. Circulation 1998; 98 (23) 2629-2635
• 18 Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 2000; 35 (5) 1103-1115
• 19 Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359 (9) 938-949
• 20 Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357 (24) 2482-2494
• 21 Kaushansky K. Regulation of megakaryopoiesis. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003. :xviii, 1142 1120–1133
• 22 Johnson PC. Platelet-mediated thrombosis in microvascular surgery: new knowledge and strategies. Plast Reconstr Surg 1990; 86 (2) 359-367
• 23 Ruggeri ZM, Orje JN, Habermann R, Federici AB, Reininger AJ. Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood 2006; 108 (6) 1903-1910
• 24 Mandarino WA, Berceli SA, Sheppeck RA, Borovetz HS. Experimental determination of velocity profiles and wall shear rate along the rabbit aortoiliac bifurcation: relationship to vessel wall low-density lipoprotein (LDL) metabolism. J Biomech 1992; 25 (9) 985-993
• 25 Johnson PC, Barker JH. Thrombosis and antithrombotic therapy in microvascular surgery. Clin Plast Surg 1992; 19 (4) 799-807
• 26 Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332 (23) 1553-1559
• 27 Zampetaki A, Kirton JP, Xu Q. Vascular repair by endothelial progenitor cells. Cardiovasc Res 2008; 78 (3) 413-421
• 28 Hill JM, Zalos G, Halcox JPJ , et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348 (7) 593-600
• 29 Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl) e89S-119S
• 30 Angiolillo DJ, Bhatt DL, Gurbel PA, Jennings LK. Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol 2009; 103 (3 Suppl): 40A-51A
• 31 Weitz JI, Eikelboom JW, Samama MM. American college of chest p. new antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl): e120S-e151S
• 32 Herbert JM, Frehel D, Vallee E , et al. Clopidogrel, a Novel Antiplatelet and Antithrombotic Agent. Cardiovasc Drug Rev 1993; 11 (2) 180-198
• 33 Brandt JT, Payne CD, Wiviott SD , et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153 (1) e9-e16
• 34 Jernberg T, Payne CD, Winters KJ , et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27 (10) 1166-1173
• 35 Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000; 284 (12) 1549-1558
• 36 Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003; 2 (1) 15-28
• 37 Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996; 88 (3) 907-914
• 38 Starnes HB, Patel AA, Stouffer GA. Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions. Drugs 2011; 71 (15) 2009-2030
• 39 Sabatine MS, Jang IK. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Am J Med 2000; 109 (3) 224-237
• 40 Karha J, Gurm HS, Rajagopal V , et al. Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes. Am J Cardiol 2006; 98 (7) 906-910
• 41 Bledzka K, Smyth SS, Plow EF. Integrin αIIbβ3: from discovery to efficacious therapeutic target. Circ Res 2013; 112 (8) 1189-1200
• 42 Kristensen SD, Würtz M, Grove EL , et al. Contemporary use of glycoprotein IIb/IIIa inhibitors. Thromb Haemost 2012; 107 (2) 215-224
• 43 Acland R. Thrombus formation in microvascular surgery: an experimental study of the effects of surgical trauma. Surgery 1973; 73 (5) 766-771
• 44 Crossman DC. More problems with the endothelium. QJM 1997; 90 (3) 157-160
• 45 Hopewell JW, Calvo W, Jaenke R, Reinhold HS, Robbins ME, Whitehouse EM. Microvasculature and radiation damage. Recent Results Cancer Res 1993; 130: 1-16
• 46 Shi G, Meister D, Daley RA, Cooley BC. Thrombodynamics of microvascular repairs: effects of antithrombotic therapy on platelets and fibrin. J Hand Surg Am 2013; 38 (9) 1784-1789
• 47 Kroll SS, Schusterman MA, Reece GP , et al. Timing of pedicle thrombosis and flap loss after free-tissue transfer. Plast Reconstr Surg 1996; 98 (7) 1230-1233
• 48 Anderson JL, Adams CD, Antman EM , et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol 2013; 61 (23) e179-e347
• 49 O'Gara PT, Kushner FG, Ascheim DD , et al; American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the american college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol 2013; 61 (4) 485-510
• 50 O'Gara PT, Kushner FG, Ascheim DD , et al; CF/AHA Task Force. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation 2013; 127 (4) 529-555
• 51 Jneid H, Anderson JL, Wright RS , et al; 2012 Writing Committee Members; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation 2012; 126 (7) 875-910
• 52 O'Gara PT, Kushner FG, Ascheim DD , et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation 2013; 127 (4) e362-e425
• 53 Cantor WJ, Madan M, O'Shea JC , et al. Bailout use of platelet glycoprotein IIb-IIIa inhibition during coronary stent implantation: observations from the ESPRIT trial. J Invasive Cardiol 2005; 17 (7) 360-364
• 54 Latsch A, Suselbeck T, Muth N , et al. Utilization of eptifibatide for treatment of severe dissections as a bail-out procedure. Int J Cardiol 2004; 96 (2) 229-233
• 55 Haase KK, Mahrholdt H, Schröder S , et al. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty. Am Heart J 1999; 137 (2) 234-240
• 56 Muhlestein JB, Karagounis LA, Treehan S, Anderson JL. “Rescue” utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. J Am Coll Cardiol 1997; 30 (7) 1729-1734
• 57 Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992; 19 (5) 926-935
• 58 Enajat M, Aziz Mohammadi M, Debeij J, van der Hulst RR, Mureau MA. Effect of acetylsalicylic acid on microvascular thrombosis in autologous breast reconstruction. J Reconstr Microsurg 2014; 30 (1) 65-70
• 59 O'shea JC, Madan M, Cantor WJ , et al. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention. Am Heart J 2000; 140 (6) 834-839
• 60 Garbarz E, Farah B, Vuillemenot A , et al. “Rescue” abciximab for complicated percutaneous transluminal coronary angioplasty. Am J Cardiol 1998; 82 (6) 800-803 , A9
• 61 Mahrholdt H, Haase KK, Baumbach A , et al. Use of Abciximab in threatening vascular occlusion after PTCA [in German]. Z Kardiol 2000; 89 (8) 722-729
• 62 Brinkman JN, Derks LH, Klimek M, Mureau MA. Perioperative fluid management and use of vasoactive and antithrombotic agents in free flap surgery: a literature review and clinical recommendations. J Reconstr Microsurg 2013; 29 (6) 357-366